Reducing harmful nitrative stress to protect hearing during cisplatin chemotherapy
Targeting nitrative stress for treatment of cisplatin ototoxicity
Testing whether lowering harmful 'nitrative stress' in the inner ear can help people getting cisplatin chemotherapy keep their hearing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-11233289 on NIH RePORTER |
What this research studies
From my perspective as a patient, researchers are trying to understand how a chemical process called nitrative stress damages hearing cells after cisplatin chemotherapy by changing a protein called LMO4 and weakening a survival signal (STAT3). They will use lab and cochlear models to track how nitration of LMO4 leads to cell death and to test interventions that stop this process. The team will combine molecular experiments with measures of cochlear function in model systems to identify targets that could be turned into protective treatments. Findings will guide later work to develop drugs or approaches to prevent or reduce hearing loss in people treated with cisplatin.
Who could benefit from this research
Good fit: People who are receiving or planning to receive cisplatin chemotherapy and are concerned about treatment-related hearing loss would be the most relevant candidates.
Not a fit: People whose hearing loss is from causes unrelated to cisplatin, or those with long-standing permanent deafness, are unlikely to benefit directly from this work in the short term.
Why it matters
Potential benefit: If successful, this work could lead to treatments that prevent or reduce hearing loss in people who receive cisplatin chemotherapy.
How similar studies have performed: Targeting nitrative stress has reduced cell death in other tissues and models, but applying this approach specifically to prevent cisplatin-related hearing loss is relatively new.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Jamesdaniel, Samson — Wayne State University
- Study coordinator: Jamesdaniel, Samson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.